Pharmaceuticals company Granules India announced Q3FY25 results The Company voluntarily paused the production at the Gagillapur plant in Sep-24 for risk assessment on account of the US FDA observations. Subsequently, the production resumed in October in a staggered manner. Revenue from Operations of Q3FY25 stood at Rs 11,377 million, a decline of 2% YoY. Revenue share from North America increased to 77% in Q3FY25, compared to 66% in Q3FY24. Finished dosages (FD), Active Pharmaceuticals Ingredients (API) and Pharmaceutical Formulation Intermediates (PFI) contributed 76%, 12%, and 12% of revenue from operations respectively for Q3FY25. ROCE for Q3FY25 is at 16.4% as compared to 15.3% for Q3FY24. Net debt stood at Rs 8,289 million. and Net debt to EBITDA ratio was 0.90 Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “We continue to sustain our profitable growth in the finished dosages segment, driven by our North America business. We are enhancing quality and compliance through systemic improvements across our operations, including Gagillapur. Progress on our greenfield formulation expansion at GLS remains on track, reinforcing our capabilities and driving future growth.” Result PDF
Conference Call with Granules India Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Granules India announced Q2FY25 results Revenue from Operations of Q2FY25 stood at Rs 9,666 million, a decline of 19% YoY. The Company has voluntarily paused production in the Gagillapur plant in Sep-24 to reassess the potential risk on account of the US FDA observations, if any. Subsequently in October, the production was resumed in a staggered manner. Revenue share from the North America increased to 79% in Q2FY25 as compared to 67% in Q2FY24. Finished dosages (FD), Active Pharmaceuticals Ingredients (API) and Pharmaceutical Formulation Intermediates (PFI) contributed 77%, 15%, and 8% of revenue from operations respectively for Q2FY25. ROCE is at 16.9% as compared to 12.9% YoY. Net debt stood at Rs 7,973 mn and Net debt to EBITDA at 0.86x. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India, said: “Q2 sales were impacted by a voluntary pause in manufacturing and distribution from our Gagillapur facility. We delivered strong margins, supported by profitable formulations sales and a favourable product mix. Our operations also generated a healthy cash from operations of Rs. 2,007 million.” Result PDF
